azvudine - versus potential COVID-19 treatments - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.00 [0.02, 55.80]< 10%1 study (1/-)50.0 %NAnot evaluable crucial-
radiologic improvement (7-day) 19.00 [0.85, 422.73]> 10%1 study (1/-)96.7 %NAnot evaluable important-
viral clearance 28.50 [1.27, 640.66]> 10%1 study (1/-)98.1 %NAnot evaluable important-
viral clearance by day 7 28.50 [1.27, 640.66]> 10%1 study (1/-)98.1 %NAnot evaluable important-

safety endpoints 00

serious adverse events 1.00 [0.02, 55.80]< 10%1 study (1/-)50.0 %NAnot evaluable important-
adverse events 0.12 [0.01, 2.86]< 10%1 study (1/-)90.1 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.